---
title: Paper published in Clinical Cancer Research
date: "Jun 24, 2021"
layout: post
output:
  html_document:
---

[Combined EZH2 inhibition and Ikaros degradation leads to enhanced anti-tumor activity in diffuse large B-cell lymphoma](https://clincancerres.aacrjournals.org/content/early/2021/06/23/1078-0432.CCR-20-4027). Tong K, Yoon S, Isaev K, ... Kridel R. Clinical Cancer Research, 2021.

In this paper, we identify that lenalidomide allows to sensitize resistant cell line models to the effect of tazemetostat, an EZH2 inhibitor.
